Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Hong Kong
· Delayed Price · Currency is HKD 23.60
+1.45 (6.55%)
Mar 28, 2025, 4:08 PM HKT
HKG:3692 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 12,261 | 10,104 | 9,382 | 9,935 | 8,690 | Upgrade
|
| Revenue Growth (YoY) | 21.35% | 7.69% | -5.56% | 14.32% | 0.09% | Upgrade
|
| Cost of Revenue | 1,117 | 1,033 | 870.19 | 870.39 | 803.41 | Upgrade
|
| Gross Profit | 11,144 | 9,071 | 8,512 | 9,065 | 7,887 | Upgrade
|
| Selling, General & Admin | 4,508 | 4,241 | 4,148 | 4,371 | 3,862 | Upgrade
|
| Research & Development | 2,702 | 2,097 | 1,693 | 1,797 | 1,252 | Upgrade
|
| Other Operating Expenses | 50.16 | 53.9 | 63.73 | 75.91 | - | Upgrade
|
| Operating Expenses | 7,242 | 6,392 | 5,905 | 6,244 | 5,114 | Upgrade
|
| Operating Income | 3,902 | 2,679 | 2,607 | 2,821 | 2,773 | Upgrade
|
| Interest Expense | -6.69 | -66.68 | -58.14 | -52.82 | -1.65 | Upgrade
|
| Interest & Investment Income | 1,046 | 1,020 | 331.52 | 253.85 | 163.92 | Upgrade
|
| Earnings From Equity Investments | - | -2.12 | -13.86 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 21.43 | 4.57 | 44.56 | -9.31 | 63.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 87.35 | 105.25 | 117.17 | 139.34 | 10.87 | Upgrade
|
| EBT Excluding Unusual Items | 5,050 | 3,741 | 3,029 | 3,152 | 3,009 | Upgrade
|
| Gain (Loss) on Sale of Investments | 61.27 | 23.51 | -91.54 | 144.49 | 88.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.72 | 2.1 | 11.24 | 3.94 | -0.04 | Upgrade
|
| Asset Writedown | -31.98 | - | - | - | - | Upgrade
|
| Pretax Income | 5,085 | 3,766 | 2,948 | 3,300 | 3,098 | Upgrade
|
| Income Tax Expense | 713.36 | 488.65 | 364.68 | 587.18 | 529.39 | Upgrade
|
| Net Income | 4,372 | 3,278 | 2,584 | 2,713 | 2,569 | Upgrade
|
| Net Income to Common | 4,372 | 3,278 | 2,584 | 2,713 | 2,569 | Upgrade
|
| Net Income Growth | 33.39% | 26.85% | -4.76% | 5.61% | 0.48% | Upgrade
|
| Shares Outstanding (Basic) | 5,930 | 5,925 | 5,916 | 5,921 | 5,876 | Upgrade
|
| Shares Outstanding (Diluted) | 5,950 | 6,020 | 5,929 | 5,998 | 5,878 | Upgrade
|
| Shares Change (YoY) | -1.16% | 1.52% | -1.14% | 2.04% | 7.31% | Upgrade
|
| EPS (Basic) | 0.74 | 0.55 | 0.44 | 0.46 | 0.44 | Upgrade
|
| EPS (Diluted) | 0.73 | 0.52 | 0.44 | 0.44 | 0.44 | Upgrade
|
| EPS Growth | 40.62% | 19.65% | -1.29% | 1.21% | -6.34% | Upgrade
|
| Free Cash Flow | - | 2,897 | 2,468 | 2,117 | 962.83 | Upgrade
|
| Free Cash Flow Per Share | - | 0.48 | 0.42 | 0.35 | 0.16 | Upgrade
|
| Dividend Per Share | 0.316 | 0.193 | 0.088 | 0.073 | 0.065 | Upgrade
|
| Dividend Growth | 63.53% | 118.47% | 20.84% | 12.44% | - | Upgrade
|
| Gross Margin | 90.89% | 89.78% | 90.72% | 91.24% | 90.75% | Upgrade
|
| Operating Margin | 31.83% | 26.52% | 27.79% | 28.39% | 31.91% | Upgrade
|
| Profit Margin | 35.66% | 32.44% | 27.54% | 27.31% | 29.56% | Upgrade
|
| Free Cash Flow Margin | - | 28.67% | 26.31% | 21.31% | 11.08% | Upgrade
|
| EBITDA | 4,248 | 3,025 | 2,932 | 3,084 | 2,989 | Upgrade
|
| EBITDA Margin | 34.64% | 29.94% | 31.25% | 31.04% | 34.40% | Upgrade
|
| D&A For EBITDA | 345.63 | 345.63 | 324.37 | 263.42 | 216.35 | Upgrade
|
| EBIT | 3,902 | 2,679 | 2,607 | 2,821 | 2,773 | Upgrade
|
| EBIT Margin | 31.83% | 26.52% | 27.79% | 28.39% | 31.91% | Upgrade
|
| Effective Tax Rate | 14.03% | 12.97% | 12.37% | 17.79% | 17.09% | Upgrade
|
Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.